FDA OKs New Drug for Chronic Idiopathic Constipation FDA OKs New Drug for Chronic Idiopathic Constipation

Lactitol (Pizensy) is an osmotic laxative taken once daily for treatment in adults with chronic idiopathic constipation.FDA Approvals
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Gastroenterology News Alert Source Type: news

Related Links:

Abstract Parkinson's disease (PD) is an age-related neurodegenerative disorder characterized by motor symptoms such as tremor, slowness of movement, rigidity, and postural instability, as well as non-motor features like sleep disturbances, loss of ability to smell, depression, constipation, and pain. Motor symptoms are caused by depletion of dopamine in the striatum due to the progressive loss of dopamine neurons in the substantia nigra pars compacta. Approximately 10% of PD cases are familial arising from genetic mutations in α-synuclein, LRRK2, DJ-1, PINK1, parkin, and several other proteins. The majority ...
Source: Current Protocols in Neuroscience - Category: Neuroscience Authors: Tags: Curr Protoc Neurosci Source Type: research
Transcutaneous electrical nerve stimulation (TENS) is primarily used for pain, but might be useful for various other physical symptoms, including nausea, fatigue, dyspnea, and constipation. However, few studies have used TENS for treating the physical symptoms of patients with advanced cancer. In this crossover trial, we assess the effects of TENS on pain and other physical symptoms in 20 in-patients with advanced cancer receiving palliative care. For 5-day phases between wash out periods of 5 days, patients received TENS or non-TENS. TENS was delivered at four points: the center of the back for mainly nausea and dyspnea, ...
Source: International Journal of Rehabilitation Research - Category: Rehabilitation Tags: Original Articles Source Type: research
First step in evaluating a woman with clinical suspicion of leiomyomas is to look into typical symptoms such as heavy or prolonged menstrual bleeding, bulk related symptoms (pelvic pressure or pain, constipation, and dyspareunia) or reproductive dysfunction. Fibroids are sometimes found in asymptomatic women during routine pelvic examination or incidentally during imaging. The clinician should also perform a precise physical examination comprising of abdominal and pelvic examination. The abdominal examination should include palpation for a pelvic or abdominal mass and the uterine fundus should be noted.
Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology - Category: OBGYN Authors: Tags: Full length article Source Type: research
Irritable bowel syndrome (IBS) is one of the most common functional bowel disorder worldwide (Clin Gastroenterol Hepatol 2012;10:712-721). The diagnosis is based on a patient reporting a specific combination of symptoms, as defined by the Rome criteria: abdominal pain, which is related to defecation, associated with a change in stool frequency or form (Gastroenterology 2016;150:1393-1407). IBS is further sub-grouped dependent on predominant stool form, be that diarrhea (IBS-D), constipation (IBS-C), or mixed stool pattern (IBS-M).
Source: Gastroenterology - Category: Gastroenterology Authors: Source Type: research
CONCLUSION: Accurate prognostic awareness may pose harm and may provide no additional benefits in terms of QoL and mood among patients with advanced cancer for a short period of time. PMID: 32052654 [PubMed - as supplied by publisher]
Source: The American Journal of Hospice and Palliative Care - Category: Palliative Care Authors: Tags: Am J Hosp Palliat Care Source Type: research
Anorexia and cachexia, nausea and vomiting, and constipation are gastrointestinal symptoms that commonly accompany serious illness. Basic science and clinical research continue to improve the understanding of their pathophysiology. Thorough assessment necessitates history, physical examination, and laboratory and diagnostic testing. Pharmacologic management attempts to counteract or reverse the underlying pathophysiologic mechanisms that accompany each symptom, which may benefit from a multimodal approach to achieve adequate control. Future improvements in management require investments in clinical research to determine th...
Source: Medical Clinics of North America - Category: Primary Care Authors: Source Type: research
Authors: Mozaffari S, Nikfar S, Daniali M, Abdollahi M Abstract Introduction: Constipation is common in patients with Parkinson's disease (PD). Due to the considerable negative outcomes of constipation, significant efforts have been made to prevent and manage chronic constipation in these patients.Areas covered: Herein, the authors review some of the known pathophysiological causes for slow gastrointestinal (GI) transit in PD patients and the different pharmacological options. All relevant clinical and experimental data found through online databases were included. Bulking agents, osmotic and stimulant laxatives, c...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Abstract Constipation is a highly prevalent functional gastrointestinal disorder that may significantly affect the quality of life and health care costs. Treatment for constipation has been broadly reviewed by cognitive therapies, medications, and surgical interventions. Gut microbiota such as Bifidobacterium, Clostridium, Bacteroidetes, and Lactobacilli have been demonstrated in functional gastrointestinal disorders and prebiotics play a role in augmenting their presence. Prebiotics are ingredients in foods that remain undigested that may stimulate bacteria. There are variety of prebiotics however there only a ha...
Source: Current Clinical Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Clin Pharmacol Source Type: research
Condition:   Constipation Intervention:   Drug: Polyethylene Glycol 3350 Sponsor:   University of Chicago Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
RARITAN, NJ, February 10, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX® (daratumumab) in combination with Kyprolis® (carfilzomib) and dexamethasone (DKd) for relapsed/refractory multiple myeloma. The sBLA is supported by results from the Phase 3 CANDOR study, which compared treatment with DKd to carfilzomib and dexamethasone (Kd) in patients with multiple myeloma who relapsed after one to three prior lines of therapy. “Wh...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
More News: Constipation | Gastroenterology